US regulatory status: approved.
pharma · Unresectable Hepatocellular Carcinoma (HCC) · Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
Zenshine Pharmaceuticals
Nanjing Zenshine Pharmaceuticals
Zenshine Pharmaceuticals drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
2018 Founded
12 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2018
- Employees
- 12
- Programs
- 8
- Drugs
- 17
- Patents
- 0
Zenshine Pharmaceuticals pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Zenshine Pharmaceuticals drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Zenshine Pharmaceuticals in public FDA and regional records.